Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer

Clinical Cancer Research

Volumn 4, Issue 7, 1998, Pages 1679-1688

  Kramer, Elissa Lipcon ^a   Liebes, Leonard ^a   Wasserheit, Carolyn ^a   Noz, Marilyn E ^a   Blank, Edward W ^b   Zabalegui, Adela ^a   Melamed, Jonathan ^a   Furmanski, Philip ^a,c   Peterson, Jerry A ^b   Ceriani, Roberto L ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Cancer Res Inst of Contra Costa   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 ISOTHIOCYANATOBENZYL) 4 METHYLDIETHYLENETRIAMINE PENTAACETIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BRE 3; PENTETIC ACID; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DOSIMETRY; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOGENICITY; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

ADULT; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MIDDLE AGED; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 15444344197     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ceriani, R., Chan, C., Baratta, F., Ozzello, L., DeRosa, C., and Habif, D. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast cancer prognosis. Int. J. Cancer. 51: 343-354, 1992.
2. 111Inmethyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study. J. Nucl. Med., 34: 1067-1074, 1993.
3. DeNardo, S., Kramer, E., O'Donnell, R., Richman, C., Salako, Q., Shen, S., Noz, M., Glenn, S., Ceriani, R., and DeNardo, G. Radioimmunotherapy for breast cancer using yttrium-90/indium-111 BrE-3: results of a phase one clinical trial. J. Nucl. Med., 38: 1180-1185, 1997.
4. Schrier, D., Stemmer, S., Johnson, T., Kasliwal, R., Lear, J., Matthes, S., Taffs, S., Dufton, C., Glenn, S., Butchko, G., Ceriani, R., Rovira, D., Bunn, P., Shpall, E., Bearman, S., Purdy, M., Cagnoni, P., and Jones, R. High dose 90Y MX-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a Phase I trial. Cancer Res., 55 (Suppl.): 5921s-5924s, 1995.
5. 111In MX-DTPA humanized BrE-3 monoclonal antibody studies in patients with advanced breast cancer. J. Nucl. Med., 38: 252P-253P, 1997.
6. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55 (Suppl.): 5916s-5920s, 1995.
7. Haga, Y., Sivinski, C., Kay, H., McDonald, G., Khazaeli, M., Blottiere, H., Steplewski, Z., Harvey, E., and Tempero, M. Biologic responses to multiple high doses of murine monoclonal antibody (17-1A) in pancreatic cancer patients. Antibody Immunoconj. Radiopharm., 5: 179-190, 1992.
8. Breitz, H., Weiden, P., Vanderheyden, J-L., Appelbaum, J., Bjorn, M., Fer, M., Wolf, S., Ratliff, B., Seiler, C., Foisie, D., Fisher, D., Schroff, R., Fritzberg, A., and Abrams, P. Clinical experience with Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of Phase I trials. J. Nucl. Med., 33: 1099-1109, 1992.
9. Scheinberg, D., Lovett, D., Divgi, C., Graham, M., Berman, E., Pentlow, K., Feirt, N., Finn, R., Clarkson, B., Gee, T., Larson, S., Oettgen, H., and Old, L. A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol., 9: 478-490, 1991.
10. Khazaeli, M., Saleh, M., Wheeler, R., Huster, W., Holden, H., Carrano, R., and LoBuglio, A. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J. Natl. Cancer Inst., 80: 937-942, 1988.
11. Juweid, M., Sharkey, R., Markowitz, A., Behr, T., Swayne, L., Dunn, R., Hansen, H., Shevitz, J., Leung, S-O., Rubin, A., Herskovic, T., Hanley, D., and Goldenberg, D. Treatment of non-Hodgkin's Iym-phoma with radiolabeled, murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 55 (Suppl.): 5899s-5907s, 1995.
12. Meredith, R., LoBuglio, A., Plott, W., Orr, R., Brezovich, I., Russell, C., Harvey, E., Yester, M., Wagner, A., Spencer, S., Wheeler, R., Saleh, M., Rogers, K., Polansky, A., Salter, M., and Khazaeli, M. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,κ 17-1A monoclonal antibody. J. Nucl. Med., 32: 1162-1168, 1991.
13. Meredith, R., Khazaeli, M., Plott, W., Saleh, M., Liu, T., Alien, L., Russell, C., Orr, R., Colcher, D., Schlom, J., Schochat, D., Wheeler, R., and LoBuglio, A. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J. Nucl. Med., 33: 23-29, 1992.
14. Meredith, R., Khazaeli, M., Plott, W., Spencer, S., Wheeler, R., Brady, L., Woo, D., and LoBuglio, A. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J. Nucl. Med., 36: 2229-2233, 1995.
15. Weiden, P., Breitz, H., Seiler, C., Bjorn, M., Ratliff, B., Mallett, R., Beaumier, P., Appelbaum, J., Fritzberg, A., and Salk, D. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J. Nucl. Med., 34: 2111-2119, 1993.
16. Ceriani, R., Blank, E., Couto, J., and Peterson, J. Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms. Cancer Res., 55 (Suppl. 23): 5852s-5856s, 1995.
17. Couto, J., Christian, R., Peterson, J., and Ceriani, R. Designing human consensus antibodies with minimal positional templates. Cancer Res., 55 (Suppl. 23): 5973s-5977s, 1995.
18. Ceriani, R., Peterson, J., Blank, E., and Lamport, D. Epitope expression on the breast epithelial mucin. Breast Cancer Res. Treat., 24: 103-113, 1992.
19. Brechbiel, M. W., Gansow, O. A., Atcher, R. W., Schlom, J., Esteban, J., Simpson, D. E., and Colcher, D. Synthesis of 1 (p-isothio-cyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem., 25: 2772-2781, 1986.
20. Macey, D., DeNardo, G., and DeNardo, S. A treatment planning program for radioimmunotherapy. The present and future role of monoclonal antibodies in the management of cancer. In: J. Vaeth and J. Meyer (eds.), Frontiers in Radiation Therapy and Oncology, pp. 123-131. Basel: Karger, 1990.
21. Noz, M., Kramer, E., Jr., Maguire, G., Jr., McGee, S., and Sanger, J. An integrated approach to biodistribution radiation absorbed dose estimates. Eur. J. Nucl. Med., 20: 165-169, 1993.
22. 111Indium-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Am. J. Physiol. Imaging, 3: 1-6, 1988.
23. Watson, E., Stabin, M., and Bolch, W. MIRDOSE. 2 2. Oak Ridge, TN: Oak Ridge Associated Universities, 1984.
24. Snyder, W., Ford, M., Warner, G., and Watson, S. MIRD pamphlet no. 11: "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. Oak Ridge, TN: Oak Ridge National Lab, 1975.
25. DeNardo, S., Warhoe, K., O'Grady, L., Hellstrom, I., Hellstrom, K. E., Mills, S. L., Macey, D. J., Goodnight, J. E., and Denardo, G. L. Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L-6 chimeric monoclonal antibody. Int. J. Biol. Markers, 6: 221-230, 1991.
26. Berger, M. Energy of deposition in water by photons from point isotropic sources, MIRD pamphlet no. 2. J. Nucl. Med., 9 (Suppl. 1): 17-26, 1968.
27. Bunn, P. A., Dienhart, D., Gonzalez, R., Kasliwal, R., Bloedow, D., Johnson, T., Lear, J., Hartmann, C., Glenn, S., Butchko, G., Maddock, S., and Ceriani, R. Imaging and treatment of patients with metastatic breast cancer with radiolabelled monoclonal antibodies. Fourth International Workshop on Monoclonal Antibodies and Breast Cancer, San Francisco, CA, November 4-5, 1990.
28. 90Yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a Phase 1 radioimmunotherapy trial. Cancer Res.. 55 (Suppl.): 5929s-5934s, 1995.
29. Caron, P., Jurcic, J., Scott, A., Finn, R., Divgi, C., Graham, M., Jureidini, I., Sgouros, G., Tyson, D., Old, L., Larson, S., and Scheinberg, D. A Phase 1B trial of humanized monoclonal antibody M195 (Anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83: 1760-1768, 1994.
30. Hakimi, J., Chizzonite, R., Luke, D., Familletli, P., Ballon, P., Kondas, J., Pilson, R., Lin, P., Weber, D., Spence, C., Mondin, L., Tsien, W-H., Levin, J., Gallati, V., Korn, L., Waldmann, T., Queen, C., and Benjamin, W. Reduced immunogenicity and improved pharmaco-kinetics of humanized anti-TAC in cynomologus monkeys. J. Immunol., 147: 1352-1359, 1991.
31. 131I chimeric mouse/human B72.3 (human gamma-4) monoclonal antibody in humans. Cancer Res., 51: 5461-5466, 1991.